Trial Readouts News Today

Total 2Q 2023 product revenue of $46.7 million Auvelity® 2Q 2023 net product sales of $27.6 million, representing 76% quarter-over-quarter growth Sunosi® 2Q 2023 net product...

Auvelity® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi® ex-U.S. license agreement... | May 8, 2023

07.11.2022 - Sunosi third quarter U.S. net sales of $16.8 million Auvelity launched and available in U.S. pharmacies SHARP study results announced demonstrating statistically significant improvement in cognitive function with Sunosi versus placebo ADVANCE-2 ...

09.08.2022 - Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of ...

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial - read this article along with other careers information, tips and advice on BioSpace

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

Company to host conference call today at 8:00 AM EasternNEW YORK, May 2, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharm...

Published: May 10, 2021 NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2021. “We continued to make significant strides in the quarter toward becoming a premier biopharmaceutical company focused on delivering potentially life-changing medicines to people living with ...

AXS-07 for migraine, NDA submission (2Q 2021) AXS-05 for smoking cessation, FDA meeting (3Q 2021) AXS-05 for MDD, commercial launch, if approved (2H 2021) Clinical Trial Readouts: Clinical Trial Initiations: Upcoming Scientific Conferences International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting, May 17-20, 2021 American Society for Clinical Psychopharmacology (ASCP) annual meeting, June 1-4, 2021 American Headache Society (AHS) annual meeting, June 3-6, 2021 Upc...

Published: Mar 01, 2021 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2020. “The focused execution of the Axsome team made 2020 a year of significant accomplishments. We had successful pre-NDA m...